Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mannitol increases plasma osmolality, drawing water from tissues into the intravascular space via osmotic gradient, thereby reducing intracranial pressure and promoting diuresis. Dextrose provides caloric support. Sodium chloride provides electrolytes.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Reduction of intracranial pressure (FDA approved),Promotion of diuresis in acute renal failure (FDA approved),Reduction of intraocular pressure (off-label),Cerebral edema (off-label),Enhancement of urinary excretion of toxic substances (off-label)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous: 50 to 100 g (333-667 m L) initially, then 50 g (333 m L) every 4-6 hours to maintain urine output of 30-50 m L/hr. Administer as a 15% solution with dextrose 5% in 0.45% sodium chloride.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Mannitol: 0.5-1.5 hours in normal renal function; prolonged to 24-48 hours in anuria; dextrose: 1-2 hours; negligible for sodium chloride.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Mannitol is minimally metabolized in the liver; mainly excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis. Approximately 80% of mannitol is excreted in urine within 3 hours.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal excretion of unchanged mannitol: 80-90% within 24 hours; dextrose is fully metabolized; sodium chloride is renally excreted.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Mannitol: 0% (not bound to plasma proteins); dextrose: negligible; sodium chloride: not applicable.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Mannitol: 0.2-0.5 L/kg, primarily extracellular; dextrose: ~0.2 L/kg; sodium chloride distributes in extracellular fluid.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
IV: 100% for all components; no oral bioavailability for mannitol (<10% absorbed).
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). Use with caution in oliguria; monitor urine output and renal function.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific adjustment required; use with caution in severe hepatic impairment due to fluid and electrolyte balance concerns.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
200 mg/kg to 2 g/kg as a 15% solution intravenously over 2-6 hours, not to exceed 60 g in 24 hours. Adjust based on urine output and clinical response.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Start at lower end of dosing range; monitor renal function, fluid and electrolyte status due to age-related decline in renal function.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
No FDA boxed warning.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Monitor serum electrolytes, renal function, and fluid balance,Risk of pulmonary edema or congestive heart failure in patients with cardiac disease,Risk of acute kidney injury or renal tubular necrosis with excessive doses or prolonged use,May cause fluid and electrolyte disturbances (e.g., hyponatremia, hyperkalemia),Use with caution in patients with impaired renal function,Intravenous administration: avoid extravasation, use large vein, monitor for phlebitis
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Anuria or severe renal impairment,Pulmonary edema or congestive heart failure,Active intracranial bleeding (except during craniotomy),Dehydration or hypovolemia,Known hypersensitivity to mannitol or any component
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No known food interactions. However, patients may require sodium restriction depending on their condition.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
No evidence of teratogenicity in animal studies. Use in pregnancy only if clearly needed. Mannitol crosses placenta; fetal effects may include electrolyte disturbances and dehydration. Avoid in first trimester unless benefit outweighs risk. In second and third trimesters, monitor for maternal pulmonary edema and fetal distress.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Mannitol likely excreted in breast milk due to low molecular weight. No M/P ratio available. Use with caution in lactating women; consider risk of infant dehydration or electrolyte imbalance. May suppress lactation due to diuretic effect.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy increases glomerular filtration rate, potentially enhancing mannitol clearance. No specific dose adjustment guidelines; titrate to clinical response and serum osmolality. Monitor for hypovolemia and electrolyte disturbances. Use lowest effective dose.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Monitor urine output and serum sodium closely; mannitol can cause osmotic diuresis leading to hypernatremia or hyponatremia depending on fluid status. Administer via central line due to high osmolality; extravasation causes tissue necrosis. Contraindicated in anuria, pulmonary edema, and intracranial bleeding. Use with caution in renal impairment and heart failure.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This medication may increase urination; keep track of how much you urinate.,Report any chest tightness, difficulty breathing, or swelling.,You may experience dry mouth or thirst; maintain adequate fluid intake if allowed.,This solution is for intravenous use only; do not inject into muscle or under skin.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Mannitol increases plasma osmolality, drawing water from tissues into the intravascular space via osmotic gradient, thereby reducing intracranial pressure and promoting diuresis. Dextrose provides caloric support. Sodium chloride provides electrolytes.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% is: Intravenous: 50 to 100 g (333-667 m L) initially, then 50 g (333 m L) every 4-6 hours to maintain urine output of 30-50 m L/hr. Administer as a 15% solution with dextrose 5% in 0.45% sodium chloride.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% is classified as Category A/B. No evidence of teratogenicity in animal studies. Use in pregnancy only if clearly needed. Mannitol crosses placenta; fetal effects may include electrolyte disturbances and dehydrat. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.